121 related articles for article (PubMed ID: 25015585)
21. [How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, or syphilis IgM positive serology test].
Duléry R; Giraud C; Beaumont JL; Bilger K; Borel C; Dhedin N; Thiebaut A; Willems E; Alain S; Alfandari S; Dewilde A; Jouet JP; Milpied N; Yakoub-Agha I;
Pathol Biol (Paris); 2013 Aug; 61(4):155-7. PubMed ID: 24011960
[TBL] [Abstract][Full Text] [Related]
22. [How we harmonize HSCT clinical practices among the SFGM-TC centers].
Tipton R; Yakoub-Agha I
Bull Cancer; 2016 Nov; 103(11S):S193-S197. PubMed ID: 27810144
[TBL] [Abstract][Full Text] [Related]
23. [Fourth annual series of workshops of the SFGM-TC to harmonize practices in allogeneic stem cell transplantation].
Yakoub-Agha I
Pathol Biol (Paris); 2014 Aug; 62(4):179. PubMed ID: 24954122
[No Abstract] [Full Text] [Related]
24. [Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC)].
Magro L; Forcade E; Giraud C; Granata A; Parquet N; Rohrlich PS; Terriou L; Yakoub-Agha I; Beguin Y
Bull Cancer; 2017 Dec; 104(12S):S145-S168. PubMed ID: 29174321
[TBL] [Abstract][Full Text] [Related]
25. [National patient follow-up care logbook: Guidelines by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
de Berranger E; Balcaen S; Ainaoui M; Bompoint C; Borel C; Chevallier N; de Bentzmann N; Denis V; Kerautret K; Godin S; Labat ML; Letort-Bertrand M; Porcheron S; Magro L; Yakoub-Agha I; Guiraud M
Bull Cancer; 2016 Nov; 103(11S):S273-S275. PubMed ID: 27776733
[TBL] [Abstract][Full Text] [Related]
26. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
Basić-Jukić N; Labar B
Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
[TBL] [Abstract][Full Text] [Related]
27. [How I manage respiratory syncytial virus, human herpesvirus 6 and adenovirus reactivation or infection after allogeneic stem cell transplantation: a report of the SFGM-TC].
Deconinck E; Dalle JH; Berceanu A; Chevallier P; Duléry R; Garnier A; Huynh A; Labussière-Wallet H; Nguyen Quoc S; Dewilde A; Ramon P; Yakoub-Agha I;
Pathol Biol (Paris); 2013 Aug; 61(4):149-51. PubMed ID: 24011959
[TBL] [Abstract][Full Text] [Related]
28. [General and ethical considerations for the informed consent process: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Thibert JB; Polomeni A; Yakoub-Agha I; Bordessoule D
Bull Cancer; 2016 Nov; 103(11S):S207-S212. PubMed ID: 27855949
[TBL] [Abstract][Full Text] [Related]
29. [National care logbook for patients undergoing autologous hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Porcheron S; Balcaen S; Cardinael N; Courbon C; Dendoncker C; Faivre-Lescat H; François G; Gilis L; Guiraud M; Schmitt S; Vercasson M; Adam C; Yakoub-Agha I
Bull Cancer; 2017 Dec; 104(12S):S142-S144. PubMed ID: 29128082
[TBL] [Abstract][Full Text] [Related]
30. [Polymorphism in HLA and KIR genes and the impact on hematopoietic stem cell transplantation outcomes and unrelated donor selection: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Dubois V; Brignier A; Elsermans V; Gagne K; Kennel A; Pedron B; Picard C; Ravinet A; Varlet P; Cesbron A; Delbos F; Yakoub-Agha I; Loiseau P
Bull Cancer; 2016 Nov; 103(11S):S243-S247. PubMed ID: 27855950
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
32. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
[TBL] [Abstract][Full Text] [Related]
33. [National patient follow-up care logbook: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Guenounou S; Aubrun C; Brancillon N; Bemben D; Chauvel C; Hounmenou N; Magro L; Porcheron S; Poullain M; De Bentzmann N; Gargallo G; Le Bars L; Mercier L; Yakoub-Agha I; Paul F
Bull Cancer; 2021 Dec; 108(12S):S87-S89. PubMed ID: 34756418
[TBL] [Abstract][Full Text] [Related]
34. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
35. [Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Pugnet G; Castilla-Llorente C; Puyade M; Terriou L; Badoglio M; Deligny C; Guillaume-Jugnot P; Labeyrie C; Benzidia I; Faivre H; Lansiaux P; Marjanovic Z; Bourhis JH; Faucher C; Furst S; Huynh A; Martin T; Vermersch P; Yakoub-Agha I; Farge D
Bull Cancer; 2017 Dec; 104(12S):S169-S180. PubMed ID: 29173974
[TBL] [Abstract][Full Text] [Related]
36. Role of immunosuppressive drugs for prevention of graft-v-host disease after bone marrow transplantation.
Devergie A; Esperou H; Traineau R; Varrin F; Lehn P; Gluckman E
Nouv Rev Fr Hematol (1978); 1989; 31(2):73-5. PubMed ID: 2671932
[TBL] [Abstract][Full Text] [Related]
37. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus in hematopoietic stem cell transplantation.
Fortune K; Couriel D
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):835-41. PubMed ID: 19545215
[TBL] [Abstract][Full Text] [Related]
39. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation.
Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J
Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648
[No Abstract] [Full Text] [Related]
40. Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment.
Abouelnasr A; Roy J; Cohen S; Kiss T; Lachance S
Biol Blood Marrow Transplant; 2013 Jan; 19(1):12-21. PubMed ID: 22771839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
